{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:06:50Z","timestamp":1793200010724,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2017-I2M-3-001"],"award-info":[{"award-number":["2017-I2M-3-001"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771757"],"award-info":[{"award-number":["81771757"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601433"],"award-info":[{"award-number":["81601433"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunoglobulin G4-related disease (IgG4-RD) is a newly recognized systemic, immune-mediated, and fibro-inflammatory disease. Hypocomplementemia was found in part of IgG4-RD patients especially in the setting of active disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to clarify the clinical features, treatment efficacy, and outcome in IgG4-RD patients with hypocomplementemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>312 IgG4-RD patients were recruited in our prospective cohort conducted in Peking Union Medical College Hospital. Patients were divided into hypocomplementemia group and normal complement group according to serum C3 and C4 levels measured at baseline before treatment. Low serum C3 levels (&lt;\u20090.73\u2009g\/L) and\/or C4 levels (&lt;\u20090.10\u2009g\/L) were defined as hypocomplementemia. Demographic data, clinical characteristics, laboratory parameters, treatment, and outcome of two groups were analyzed and compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Hypocomplementemia was identified in 65 (20.8%) cases of untreated IgG4-RD patients at baseline. The average age of hypocomplementemia group was 55.85\u2009\u00b1\u200910.89\u2009years, with male predominance (72.3%). Compared with normal complement group, patients with hypocomplementemia were likely to have more involved organs, higher IgG4-RD responder index (IgG4-RD RI), and higher laboratory parameters such as counts of eosinophils, inflammatory markers, immunoglobulin G (IgG), IgG1, IgG3, IgG4, and IgE. In addition, lymph nodes, lacrimal gland, submandibular gland, parotid gland, paranasal sinus, bile ducts, and prostate gland were more commonly affected (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Serum C3 and C4 showed a significant positively correlation with each other. Both C3 and C4 were negatively correlated with the number of involved organs, IgG, IgG3, IgG4, and IgG4-RD RI, as well as positively correlated with IgA and hypersensitive C reactive protein (hsCRP). 64 (98.5%) patients responded quickly to initial therapy at a 3-month follow-up. Fifteen (23.1%) patients relapsed during follow-up with mean recurrence time of 14.2\u2009\u00b1\u200913.8\u2009months. Compared with normal complement group, there was no significant difference of relapse rate in two groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.401).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical characteristics of IgG4-related disease with hypocomplementemia differ from normal complement group. Serum C3 and C4 at baseline before treatment could be biological markers for disease activity. IgG4-RD with hypocomplementemia responded well to treatment and had no significant difference of relapse rate in IgG4-RD with normal complement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-021-02481-3","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T04:04:04Z","timestamp":1617768244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Linyi","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangzhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-9867","authenticated-orcid":false,"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"9","key":"2481_CR1","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/art.39205","volume":"67","author":"ZS Wallace","year":"2015","unstructured":"Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, Stone JH. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 2015;67(9):2466\u201375. https:\/\/doi.org\/10.1002\/art.39205.","journal-title":"Arthritis Rheumatol"},{"issue":"9976","key":"2481_CR2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","volume":"385","author":"T Kamisawa","year":"2015","unstructured":"Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(14)60720-0.","journal-title":"Lancet"},{"issue":"7","key":"2481_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11882-014-0448-2","volume":"14","author":"AR Bryan","year":"2014","unstructured":"Bryan AR, Wu EY. Complement deficiencies in systemic lupus erythematosus. Curr Allergy Asthma Rep. 2014;14(7):448. https:\/\/doi.org\/10.1007\/s11882-014-0448-2.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"3","key":"2481_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S1521-6616(03)00034-2","volume":"107","author":"VM Holers","year":"2003","unstructured":"Holers VM. The complement system as a therapeutic target in autoimmunity. Clin Immunol. 2003;107(3):140\u201351. https:\/\/doi.org\/10.1016\/S1521-6616(03)00034-2.","journal-title":"Clin Immunol"},{"key":"2481_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cca.2016.12.017","volume":"465","author":"P Vignesh","year":"2017","unstructured":"Vignesh P, Rawat A, Sharma M, Singh S. Complement in autoimmune diseases. Clin Chim Acta. 2017;465:123\u201330. https:\/\/doi.org\/10.1016\/j.cca.2016.12.017.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"2481_CR6","first-page":"55","volume":"24","author":"AC Macedo","year":"2016","unstructured":"Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol. 2016;24(7):55.","journal-title":"Front Immunol"},{"issue":"42","key":"2481_CR7","doi-asserted-by":"publisher","first-page":"25343","DOI":"10.1074\/jbc.M115.647008","volume":"290","author":"VV Vasilev","year":"2015","unstructured":"Vasilev VV, Noe R, Dragon-Durey MA, Chauvet S, Lazarov VJ, Deliyska BP, Fremeaux-Bacchi V, Dimitrov JD, Roumenina LT. Functional characterization of autoantibodies against complement component C3 in patients with lupus nephritis. J Biol Chem. 2015;290(42):25343\u201355. https:\/\/doi.org\/10.1074\/jbc.M115.647008.","journal-title":"J Biol Chem"},{"issue":"6","key":"2481_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrneph.2017.37","volume":"13","author":"M Chen","year":"2017","unstructured":"Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol. 2017;13(6):359\u201367. https:\/\/doi.org\/10.1038\/nrneph.2017.37.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"2481_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/s10165-011-0571-z","volume":"22","author":"H Umehara","year":"2012","unstructured":"Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, Hamano H, Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T, Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima M, Hibi T, Tsubouchi H, Inui K, Ohara H. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21\u201330. https:\/\/doi.org\/10.3109\/s10165-011-0571-z.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"2481_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/14397595.2017.1290911","volume":"27","author":"H Umehara","year":"2017","unstructured":"Umehara H, Okazaki K, Nakamura T, Satoh-Nakamura T, Nakajima A, Kawano M, Mimori T, Chiba T. Current approach to the diagnosis of IgG4-related disease - combination of comprehensive diagnostic and organ-specific criteria. Mod Rheumatol. 2017;27(3):381\u201391. https:\/\/doi.org\/10.1080\/14397595.2017.1290911.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"2481_CR11","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.23543","volume":"70","author":"ZS Wallace","year":"2018","unstructured":"Wallace ZS, Khosroshahi A, Carruthers MD, Perugino CA, Choi H, Campochiaro C, Culver EL, Cortazar F, Della-torre E, Ebbo M, Fernandes A, Frulloni L, Hart PA, Karadag O, Kawa S, Kawano M, Kim MH, Lanzillotta M, Matsui S, Okazaki K, Ryu JH, Saeki T, Schleinitz N, Tanasa P, Umehara H, Webster G, Zhang W, Stone JH. An international multispecialty validation study of the IgG4-related disease responder index. Arthritis Care Res. 2018;70(11):1671\u20138. https:\/\/doi.org\/10.1002\/acr.23543.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"2481_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206605.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2481_CR13","doi-asserted-by":"publisher","first-page":"10262","DOI":"10.1038\/s41598-018-28405-x","volume":"8","author":"M Shirakashi","year":"2018","unstructured":"Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, Uchida K, Okazaki K, Ito T, Kawa S, Yamada K, Kawano M, Hirata S, Tanaka Y, Moriyama M, Nakamura S, Kamisawa T, Matsui S, Tsuboi H, Sumida T, Shibata M, Goto H, Sato Y, Yoshino T, Mimori T. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep. 2018;8(1):10262. https:\/\/doi.org\/10.1038\/s41598-018-28405-x.","journal-title":"Sci Rep"},{"key":"2481_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/rheumatology\/key227","volume":"58","author":"F Yunyun","year":"2018","unstructured":"Yunyun F, Yu P, Panpan Z, et al. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford, England). 2018;58:52\u201360.","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"2481_CR15","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2665-9913(19)30017-7","volume":"1","author":"W Zhang","year":"2019","unstructured":"Zhang W, Stone JH. Management of IgG4-related disease. Lancet Rheumatol. 2019;1(1):e55\u201365. https:\/\/doi.org\/10.1016\/S2665-9913(19)30017-7.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"2481_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Schleinitz N, Takahashi N, Umehara H, Zen Y, Stone JH, Members of the ACR\/EULAR IgG4-RD Classification Criteria Working Group. The 2019 American College of Rheumatology\/European league against rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79(1):77\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216561.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2481_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10157-011-0521-2","volume":"15","author":"M Kawano","year":"2011","unstructured":"Kawano M, Saeki T, Nakashima H, Nishi S, Yamaguchi Y, Hisano S, Yamanaka N, Inoue D, Yamamoto M, Takahashi H, Nomura H, Taguchi T, Umehara H, Makino H, Saito T. Proposal for diagnostic criteria or IgG4-related kidney disease. Clin Exp Nephrol. 2011;15(5):615\u201326. https:\/\/doi.org\/10.1007\/s10157-011-0521-2.","journal-title":"Clin Exp Nephrol"},{"key":"2481_CR18","first-page":"5851842","volume":"2020","author":"F Teng","year":"2020","unstructured":"Teng F, Lu H, Zhen K, et al. Urinary system manifestation of IgG4-related disease: clinical, laboratory, radiological, and pathological spectra of a Chinese single- centre study. J Immunol Res. 2020;2020:5851842.","journal-title":"J Immunol Res"},{"issue":"2","key":"2481_CR19","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaci.2018.05.011","volume":"143","author":"CA Perugino","year":"2019","unstructured":"Perugino CA, AlSalem SB, Mattoo H, et al. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. J Allergy Clin Immunol. 2019;143(2):736\u2013745.e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2481_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/gutjnl-2017-314548","volume":"67","author":"LM Hubers","year":"2018","unstructured":"Hubers LM, Vos H, Schuurman AR, Erken R, Oude Elferink RP, Burgering B, van de Graaf S, Beuers U. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut. 2018;67(4):728\u201335. https:\/\/doi.org\/10.1136\/gutjnl-2017-314548.","journal-title":"Gut"},{"issue":"453","key":"2481_CR21","doi-asserted-by":"publisher","first-page":"eaaq0997","DOI":"10.1126\/scitranslmed.aaq0997","volume":"10","author":"M Shiokawa","year":"2018","unstructured":"Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med. 2018;10(453):eaaq0997.","journal-title":"Sci Transl Med"},{"issue":"5","key":"2481_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125331","volume":"10","author":"H Du","year":"2015","unstructured":"Du H, Shi L, Chen P, et al. Prohibitin is involved in patients with IgG4 related disease. PLoS One. 2015;10(5):e0125331. https:\/\/doi.org\/10.1371\/journal.pone.0125331.","journal-title":"PLoS One"},{"issue":"1","key":"2481_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/01.mpa.0000188308.75043.e4","volume":"32","author":"T Muraki","year":"2006","unstructured":"Muraki T, Hamano H, Ochi Y, Komatsu K, Komiyama Y, Arakura N, Yoshizawa K, Ota M, Kawa S, Kiyosawa K. Autoimmune pancreatitis and complement activation system. Pancreas. 2006;32(1):16\u201321. https:\/\/doi.org\/10.1097\/01.mpa.0000188308.75043.e4.","journal-title":"Pancreas"},{"key":"2481_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/82_2016_39","volume":"401","author":"S Kawa","year":"2017","unstructured":"Kawa S. The immunobiology of immunoglobulin G4 and complement activation pathways in IgG4-related disease. Curr Top Microbiol Immunol. 2017;401:61\u201373. https:\/\/doi.org\/10.1007\/82_2016_39.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"2481_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/14397595.2015.1076924","volume":"26","author":"M Sugimoto","year":"2016","unstructured":"Sugimoto M, Watanabe H, Asano T, Sato S, Takagi T, Kobayashi H, Ohira H. Possible participation of IgG4 in the activation of complement in IgG4-related disease with hypocomplementemia. Mod Rheumatol. 2016;26(2):251\u20138. https:\/\/doi.org\/10.3109\/14397595.2015.1076924.","journal-title":"Mod Rheumatol"},{"issue":"10","key":"2481_CR26","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1111\/jgh.14512","volume":"34","author":"EL Culver","year":"2019","unstructured":"Culver EL, van de Bovenkamp FS, Derksen NIL, Koers J, Cargill T, Barnes E, de Neef LA, Koeleman CAM, Aalberse RC, Wuhrer M, Rispens T. Unique patterns of glycosylation in immunoglobulin subclass G4-related disease and primary sclerosing cholangitis. J Gastroenterol Hepatol. 2019;34(10):1878\u201386. https:\/\/doi.org\/10.1111\/jgh.14512.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02481-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-021-02481-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02481-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T04:07:18Z","timestamp":1617768438000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02481-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2481"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02481-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-150733\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"17 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Peking Union Medical College Hospital and approval number is S-442. All enrolled patients consented to attend this cohort study and signed written.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes, we obtained consent for publication from all the individuals of whom detailed information was included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}